Abstract
Background
Advanced and recurrent ovarian cancer results in extensive spread of tumor on the peritoneal surfaces of the abdomen and pelvis. We collectively review studies in the literature that report the efficacy of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer peritoneal carcinomatosis.
Methods
An electronic search of all relevant studies published in peer-reviewed journals before May 2009 was performed on three databases. The quality of each study was independently assessed and classified according to the time point of HIPEC use in various setting of ovarian cancer from the consensus statement of the Peritoneal Surface Oncology Group. Clinical efficacy was synthesized through a narrative review with full tabulation of the results of each included study.
Results
Nineteen studies each of more than ten patients reporting treatment results of HIPEC of patients with both advanced and recurrent ovarian cancer were included and data were extracted. All studies were observational case series. The overall rate of severe perioperative morbidity ranged from 0 to 40% and mortality rate varied from 0 to 10%. The overall median survival following treatment with HIPEC ranged from 22 to 64 months with a median disease-free survival ranging from 10 to 57 months. In patients with optimal cytoreduction, a 5-year survival rate ranging from 12 to 66% could be achieved.
Conclusion
Despite the heterogeneity of the studies reviewed, current evidence suggest that complete CRS and HIPEC may be a feasible option with potential benefits that are comparable with the current standard of care. A randomized trial is required to establish the role of HIPEC in ovarian cancer.
Similar content being viewed by others
References
Abu-Hijleh MF, Habbal OA, Moqattash ST (1995) The role of the diaphragm in lymphatic absorption from the peritoneal cavity. J Anat 186:453–467
Aravantinos G, Bafaloukos D, Fountzilas G, Christodoulou C, Papadimitriou C, Pavlidis N et al (2003) Phase II study of docetaxel–vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. Ann Oncol 14(7):1094–1099
Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34–43
Bae JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY et al (2007) Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol 106(1):193–200
Bereder J, Glehen O, Habre J, Desantis M, Cotte E, Mounier N et al (2009) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from ovarian cancer: a multiinstitutional study of 246 patients. J Clin Oncol 27(15s):abstr 5542
Bristow RE, Chi DS (2006) Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103(3):1070–1076
Bristow RE, Lagasse LD, Karlan BY (1996) Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature. Cancer 78(10):2049–2062
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–1259
Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH (2003) Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metast Rev 22:465–472
Cavaliere F, Perri P, Di Filippo F, Giannarelli D, Botti C, Cosimelli M et al (2000) Treatment of peritoneal carcinomatosis with intent to cure. J Surg Oncol 74(1):41–44
Chatzigeorgiou K, Economou S, Chrysafis G, Dimasis A, Zafiriou G, Setzis K et al (2003) Treatment of recurrent epithelial ovarian cancer with secondary cytoreduction and continuous intraoperative intraperitoneal hyperthermic chemoperfusion (CIIPHCP). Z Gynäkol 125(10):424–429
Chua TC, Liauw W, Robertson G, Chia WK, Soo KC, Alobaid A et al (2009a) Towards randomized trials of peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis. Gynecol Oncol, Epub
Chua TC, Yan TD, Saxena A, Morris DL (2009b) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg, Epub
Cotte E, Glehen O, Mohamed F, Lamy F, Falandry C, Golfier F et al (2007) Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg 31(9):1813–1820
de Bree E, Romanos J, Michalakis J, Relakis K, Georgoulias V, Melissas J et al (2003) Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res 23(3c):3019–3027
Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M et al (2008) Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 113(2):315–325
Fagotti A, Paris I, Grimolizzi F, Fanfani F, Vizzielli G, Naldini A et al (2009) Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study. Gynecol Oncol 113(3):335–340
Ferrandina G, Ludovisi M, De Vincenzo R, Salutari V, Lorusso D, Colangelo M et al (2007) Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. Ann Oncol 18(8):1348–1353
Goff BA, Mandel L, Muntz HG, Melancon CH (2000) Ovarian carcinoma diagnosis. Cancer 89(10):2068–2075
Gori J, Castano R, Toziano M, Habich D, Staringer J, De Quiros DGB et al (2005) Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer 15(2):233–239
Guardiola E, Delroeux D, Heyd B, Combe M, Lorgis V, Demarchi M et al (2009) Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer. World J Surg Oncol 9(7):14
Helm CW, Randall-Whitis L, Martin RS III, Metzinger DS, Gordinier ME, Parker LP et al (2007) Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol 105(1):90–96
Helm CW, Bristow RE, Kusamura S, Baratti D, Deraco M (2008) Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol 98:283–290
Jacquet P, Sugarbaker PH (1996) Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 15:49–58
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43–66
Look M, Chang D, Sugarbaker PH (2004) Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 14:35–41
Matsumoto A, Higuchi T, Yura S, Mandai M, Kariya M, Takakura K et al (2006) Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy. J Obstet Gynaecol Res 32(6):580–587
Ozols RF (2002) Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol 20(5):1161–1163
Ozols RF (2005) Treatment goals in ovarian cancer. Int J Gynecol Cancer 15(suppl 1):3–11
Pavlov MJ, Kovacevic PA, Ceranic MS, Stamenkovic AB, Ivanovic AM, Kecmanovic DM (2009) Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer—12-year single center experience. Eur J Surg Oncol (in press)
Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ et al (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24(29):4699–4707
Piso P, Dahlke MH, Loss M, Schlitt HJ (2004) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2(21)
Raspagliesi F, Kusamura S, Campos Torres JC, de Souza GA, Ditto A, Zanaboni F et al (2006) Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol 32(6):671–675
Reichman TW, Cracchiolo B, Sama J, Bryan M, Harrison J, Pliner L et al (2005) Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. J Surg Oncol 90(2):51–56 (discussion 56–58)
Rowan K (2009) Intraperitoneal therapy for ovarian cancer: why has it not become standard? J Natl Cancer Inst, Epub
Rufian S, Munoz-Casares FC, Briceno J, Diaz CJ, Rubio MJ, Ortega R et al (2006) Radical surgery–peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 94(4):316–324
Ryu KS, Kim JH, Ko HS, Kim JW, Ahn WS, Park YG et al (2004) Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol 94(2):325–332
Salani R, Santillan A, Zahurak ML, Giuntoli RL II, Gardner GJ, Armstrong DK et al (2007) Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 109(4):685–691
Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40(2):256–260
Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221(1):29–42
Sugarbaker PH (1996) Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: principles of management. Kluwer, Boston
Sugarbaker PH (2007) Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperth 23(5):431–442
Trimble EL, Christian MC (2008) National Cancer Institute—United States strategy regarding intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer 18(suppl 1):26–28
Vergote I, Tropé CG, Amant F, Kristensen GB, Sardi JE, Ehlen T et al (2008) EORTC-GCG/NCIC-CTG randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC–IV ovarian, fallopian tube and peritoneal cancer (OVCA). Paper presented at the 12th Biennial Meeting International Gynecologic Cancer Society—IGCS, Bangkok, Thailand
Walker JL (2009) Intraperitoneal chemotherapy for ovarian cancer: 2009 goals. Gynecol Oncol 112(3):439–440
Walker JL, Armstrong DK, Huang HQ, Fowler JM, Webster K, Burger RA et al (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 100:27–32
Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG et al (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25(24):3621–3627
Witkamp AJ, De Bree E, Van Goethem AR, Zoetmulder FAN (2001) Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 27:365–374
Yan TD, Black D, Savady R, Sugarbaker PH (2006) Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 24(24):4011–4019
Yan TD, Black D, Savady R, Sugarbaker PH (2007a) A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 14(2):484–492
Yan TD, Welch L, Black D, Sugarbaker PH (2007b) A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18(5):827–834
Zanon C, Clara R, Chiappino I, Bortolini M, Cornaglia S, Simone P et al (2004) Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg 28:1040–1045
Conflict of interest
All authors have no conflict of interest to declare.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Chua, T.C., Robertson, G., Liauw, W. et al. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol 135, 1637–1645 (2009). https://doi.org/10.1007/s00432-009-0667-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-009-0667-4